Chromosomal Microarray Analysis as First-Tier Genetic Test for Schizophrenia

Chia Hsiang Chen*, Min Chih Cheng, Tsung Ming Hu, Lieh Yung Ping

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

4 Scopus citations


Schizophrenia is a chronic, devastating mental disorder with complex genetic components. Given the advancements in the molecular genetic research of schizophrenia in recent years, there is still a lack of genetic tests that can be used in clinical settings. Chromosomal microarray analysis (CMA) has been used as first-tier genetic testing for congenital abnormalities, developmental delay, and autism spectrum disorders. This study attempted to gain some experience in applying chromosomal microarray analysis as a first-tier genetic test for patients with schizophrenia. We consecutively enrolled patients with schizophrenia spectrum disorder from a clinical setting and conducted genome-wide copy number variation (CNV) analysis using a chromosomal microarray platform. We followed the 2020 “Technical Standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen)” to interpret the clinical significance of CNVs detected from patients. We recruited a total of 60 patients (36 females and 24 males) into this study. We detected three pathogenic CNVs and one likely pathogenic CNV in four patients, respectively. The detection rate was 6.7% (4/60, 95% CI: 0.004–0.13), comparable with previous studies in the literature. Also, we detected thirteen CNVs classified as uncertain clinical significance in nine patients. Detecting these CNVs can help establish the molecular genetic diagnosis of schizophrenia patients and provide helpful information for genetic counseling and clinical management. Also, it can increase our understanding of the pathogenesis of schizophrenia. Hence, we suggest CMA is a valuable genetic tool and considered first-tier genetic testing for schizophrenia spectrum disorders in clinical settings.

Original languageEnglish
Article number620496
JournalFrontiers in Genetics
StatePublished - 01 10 2021

Bibliographical note

Publisher Copyright:
© Copyright © 2021 Chen, Cheng, Hu and Ping.


  • chromosome microarray analysis
  • copy number variation
  • genetic test
  • rare mutation
  • schizophrenia


Dive into the research topics of 'Chromosomal Microarray Analysis as First-Tier Genetic Test for Schizophrenia'. Together they form a unique fingerprint.

Cite this